The HIVEP1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population in which the HIVEP1 gene has been disrupted in the HT29 human colorectal adenocarcinoma cell line. This model provides a powerful tool for loss-of-function studies, capturing the genetic heterogeneity of a polyclonal pool to facilitate robust screening of HIVEP1-dependent processes in an intestinal epithelial context.
The HT29 host cell line is a well-established epithelial model derived from a primary colorectal adenocarcinoma. These cells retain the capacity for enterocytic differentiation and are extensively used for investigating intestinal barrier function, mucosal immunity, and colorectal cancer biology. HT29 cells express key pattern recognition receptors and are highly responsive to pro-inflammatory stimuli such as TNF-alpha and IL-1, offering a relevant setting for studying NF-kB-mediated signaling.
HIVEP1 encodes a zinc-finger transcription factor that directly binds the NF-kB enhancer motif and modulates the expression of immune and inflammatory genes. Its activation is triggered by TNF-alpha, IL-1, or Toll-like receptor ligands, which stimulate the IKK complex (including IKBKB) to phosphorylate and degrade NFKBIA (IkB-alpha). This releases RELA/p50 dimers to translocate into the nucleus, where HIVEP1 collaborates with these subunits and recruits co-activators such as CBP/p300 to drive transcription of downstream targets, including IL-6, IL-8, TNF-alpha, specific chemokines, and adhesion molecules. HIVEP1 also interacts with TRAF2-RIPK1 signalosomes and may intersect with Wnt signaling, linking inflammatory and oncogenic pathways.
Disruption of HIVEP1 in the HT29 background is expected to impair NF-kB-dependent transcription and dampen the production of key inflammatory mediators. This defect can alter autocrine cytokine loops, cell survival, migration, and epithelial-to-mesenchymal transition potential. The model therefore enables precise dissection of HIVEP1??s role in colorectal cancer progression, inflammatory bowel disease pathogenesis, and the regulation of intestinal epithelial barrier function under inflammatory or chemotherapeutic stress.
Researchers can utilize these polyclonal knockout cells for western blot analysis of HIVEP1, RELA, and phospho-IKK, as well as RT-qPCR quantification of IL-6, IL-8, and TNF-alpha transcripts. NF-kB activation is readily monitored by luciferase reporter or immunofluorescence for RELA nuclear translocation, while ChIP-qPCR can map HIVEP1 binding sites. Functional assays including scratch wound migration, transwell invasion, and drug sensitivity testing with colorectal cancer therapeutics or pathway inhibitors further broaden the utility of this model. For further information, please contact Ascent Research.
